| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| License fee revenue | 18,025 | - | ||
| Cost of revenues | 20,687 | - | ||
| Gross profit (loss) | -2,662 | - | ||
| Compensation expense | 227,132 | - | ||
| Professional fees | 313,194 | - | ||
| Research and development | 543,615 | - | ||
| Other selling, general and administrative expenses | 64,863 | - | ||
| Total operating expenses | 1,148,804 | - | ||
| Loss from operations | -1,151,466 | - | ||
| Interest and dividend income, net | 44,604 | - | ||
| Interest expense | 886 | - | ||
| Unrealized loss on crypto assets | 2,690 | - | ||
| Provision for income taxes | - | 0 | ||
| Total other income, net | 41,028 | - | ||
| Loss before provision for income taxes | -1,110,438 | -1,204,293 | ||
| Net loss | -1,110,438 | -1,204,293 | ||
| Unrealized gain on short-term debt investments | 1,781 | -1,140 | ||
| Total comprehensive loss | -1,108,657 | -1,205,433 | ||
| Basic (in dollars per share) | -0.12 | -0.19 | ||
| Basic (in shares) | 9,331,346 | 6,279,733 | ||
| Diluted (in dollars per share) | -0.12 | -0.19 | ||
| Diluted (in shares) | 9,331,346 | 6,279,733 | ||
Silo Pharma, Inc. (SILO)
Silo Pharma, Inc. (SILO)